RED+BLUE STRATEGIES for EXPRESS SCRIPTS INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 6 - 21st Century Cures- Provisions focused on preventing opioid abuse and additional years of exclusivity for certain prescription medications Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Policies related to ending the abuse of prescription medications. Issues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs. Issues related to the pricing of prescription medications.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Medicare/Medicaid MMM
H.R.6 - 21st Century Cures - Issues related to improving polices to prevent prescription drug abuse among participants in the Medicare Part D program. Policies and regulations focused on Medicare Part C and Part D with a focus on coverage of prescription medications, formulary design and access to specialty drugs. Policies focused on ensuring affordable access to Biosimilar medications for Medicare and Medicaid beneficiaries as well as those in the private market. Policies focused on ending prescription drug abuse in the Medicare Part D program. Issues related to the Medicare Call letter related to preferred pharmacy networks in Medicare Part D. ACA- related regulations impacting Federal and State Based Marketplaces'' coverage of prescription medications. Issues related to cost of and access to specialty medications and their impact on consumers and purchasers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Pharmacy PHA
H.R.6 - 21st Century Cures - Issues related to exclusivity rights of certain prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN HAUCK MARSHALL | — |
| MELANIE JAN NATHANSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.